|
Myeloid Leukemia, Chronic
|
0.500 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Myeloid Leukemia, Chronic
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We found plasma levels of total JAK2 mRNA to be higher in patients with non-CML MPD (n=175) than in CML patients (n=45) and normal controls (n=58) (each P<0.001).
|
19254349 |
2010 |
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
Additionally, the JAK2/STAT3 signalling pathway, which is abnormally active in CML, was inhibited by MBD2 deletion, and MBD2 deletion could up-regulate the expression of SHP1.
|
29565710 |
2018 |
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
In myeloid diseases we have seen dramatic improvements in the overall survival and quality of life for patients with chronic myeloid leukaemia treated with ABL and Src/ABL kinase inhibitors and we are poised to discover whether JAK2 inhibitors may offer similar benefit in myeloproliferative diseases.
|
20041451 |
2010 |
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
Inhibition of JAK-2 overcomes GM-CSF-induced IM and NI progenitor cell resistance, providing a rationale for the application of JAK-2 inhibitors to eradicate residual disease in CML.
|
17090651 |
2007 |
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
Alternative TEL-JAK2 fusions associated with T-cell acute lymphoblastic leukemia and atypical chronic myelogenous leukemia dissected in zebrafish.
|
22733019 |
2012 |
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
LHGDN |
Hematopoietic perturbation in zebrafish expressing a tel-jak2a fusion.
|
15676212 |
2005 |
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
These results identify Jak2 as a potentially important therapeutic target for CML.
|
16818614 |
2006 |
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
The patient was diagnosed with CML and <i>JAK2 V617F</i> mutation.
|
31123683 |
2019 |
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
Simultaneously targeting BCR-ABL and JAK2 activities in CML stem/progenitor cells may improve outcomes in patients destined to develop IM resistance.
|
23446755 |
2013 |
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
Here we review results of recent studies with first-generation JAK2 inhibitors in the treatment of MPN and second-generation ABL and Flt3 inhibitors in CML and AML, respectively.
|
20809224 |
2010 |
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
We recently demonstrated that the AHI-1 oncogene physically interacts with BCR-ABL and JAK2 and mediates cellular resistance to TKI in CML stem/progenitor cells.
|
22623184 |
2012 |
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
HPO |
|
|
|
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
Therefore, inhibitors of JAK2 kinases are turning into therapeutic strategies for treatment of chronic myelogenous leukemia (CML).
|
24504330 |
2014 |
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
We address recent updates in the genetics and epigenetics of MPN, the mechanisms of transformation by mutant calreticulin, advances in the biology and therapy of systemic mastocytosis, clinical updates on JAK2 inhibitors and other therapeutic approaches for patients with MPNs, cardiovascular toxicity related to tyrosine kinase inhibitors and the concept of treatment-free remission for patients with CML.
|
29466766 |
2018 |
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
A translocation generating the constitutively activated fusion protein PCM1-JAK2 has also been recently found in atypical chronic myelogenous leukemia and acute leukemia.
|
16007127 |
2005 |
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
Consequently, JAK2 inhibitors represent promising molecular therapeutic tools in CML.
|
29423056 |
2018 |
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
A new AHI-1-BCR-ABL-JAK2 interaction complex has recently been identified and this complex regulates transforming activities and drug resistance in CML stem/progenitor cells.
|
22248740 |
2011 |
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia.
|
24813920 |
2015 |
|
Myeloid Leukemia, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Considerable effort is being made to understand the role of JAK2(V617F) at the MPN initiation and to clarify the pathogenesis and apoptosis resistance in CML, PV, ET and PMF patients.
|
27282563 |
2016 |
|
Myeloid Leukemia, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia.
|
16001431 |
2005 |
|
Myeloid Leukemia, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Herein, the authors present three cases of CML diagnosed within five years of treatment initiation for Hodgkin's Lymphoma (HL); one of the three patients had CML with atypical variant carrying a rare mutation with BCR-JAK2 fusion.
|
31366526 |
2019 |
|
Myeloid Leukemia, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Abnormalities of tyrosine kinase proteins are well recognised in myeloid malignancies, mutation in the cytoplasmic tyrosine kinase JAK2 (V617F) is key in the pathogenesis of myeloproliferative neoplasms, and translocations involving ABL key in the development of chronic myeloid leukaemia.
|
21722956 |
2011 |
|
Myeloid Leukemia, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
JAK2 mutation was also detected in 3 (19%) of 16 patients with Philadelphia-chromosome (Ph)-negative chronic myelogenous leukemia (CML), 2 (18%) of 11 patients with megakaryocytic AML, 7 (13%) of 52 patients with chronic myelomonocytic leukemia, and 1 (1%) of 68 patients with myelodysplastic syndromes.
|
16037387 |
2005 |
|
Myeloid Leukemia, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We studied samples from 1088 persons with myeloproliferative neoplasms (MPNs) including 421 JAK2(V617F) negative subjects with ET, PMF, polycythemia vera (PV), chronic myeloid leukemia (CML) and hyper-eosinophilic syndrome (HES).
|
25860380 |
2015 |